EGFR and neoplasm: Scherpereel et al. (2003) found that intrathecal injection of the MEP 08 mAb, a specific mAb that recognizes the phenylalanine-rich region of endocan, could delay tumor appearance in vivo by acting against endocan-dependent tumorigenesis. In addition, Yang et al. (2020) demonstrated that a synthetic peptide corresponding to residues 1-27 of endocan, which is part of the N-terminal region critical for endocan’s interaction with EGFR, may reduce lung tumor growth by blocking the binding of endocan to the extracellular domain of EGFR.